Decreased prostatic arachidonic acid in human prostatic carcinoma

BJU International

Volumn 92, Issue 6, 2003, Pages 551-554

  Faas, F H ^a,b   Dang, A Q ^a   White, J ^a   Schaefer, R F ^a   Johnson, D E ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Arachidonic acid; Fatty acids; Prostate cancer

Indexed keywords

ARACHIDONIC ACID; LEUKOTRIENE; PROSTAGLANDIN;

ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; CYSTECTOMY; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; TRANSURETHRAL RESECTION;

ARACHIDONIC ACID; FATTY ACIDS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NECK OBSTRUCTION;

EID: 0142028779     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04387.x     Document Type: Article

References (14)

1. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst 1999; 91: 414-28
2. Persad RA, Gillatt DA, Heinemann D, Habib NA, Smith PJ. Erythrocyte stearic to oleic acid ratio in prostatic carcinoma. Br J Urol 1990; 65: 268-70
3. Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991; 64: 1157-60
4. Godley PA, Campbell MD, Gallagher P, Martinson FE, Mohler JL, Sandler RS. Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiol, Biomarkers Prev 1996; 5: 889-95
5. Gann PH, Hennekens CH, Sacks FM, Grodstein F, Giovannucci EL, Stampfer MJ. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994; 86: 281-6
6. Chaudry AA, Wahle KW, McClinton S, Moffatt LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57: 176
7. Ghosh J, Myers CE. Arachidonic acid metabolism and cancer of the prostate. Nutrition 1998; 14: 48-9
8. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 1999; 81: 1238-42
9. Narayan P, Dahiya R. Alterations in sphingomyelin and fatty acids in human benign prostatic hyperplasia and prostatic cancer. Biomed Biochim Acta 1991; 50: 1099-108
10. Faas FH, Dang AQ, Pollard M et al. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol 1996; 156: 243-8
11. Freeman VL, Meydani M, Yong S et al. Prostatic levels of fatty acids and the histopathology of localized prostate cancer. J Urol 2000; 164: 2168-72
12. Faas FH, Dang AQ, White J, Schaefer R, Johnson D. Increased prostatic lysophosphatidylcholine acyltransferase activity in human prostate cancer: a marker for malignancy. J Urol 2001; 165: 463-8
13. Dang AQ, Faas FH, Lee JA, Carter WJ. Altered fatty acid composition in the plasma, platelets, and aorta of the streptozotocin-induced diabetic rat. Metabolism 1988; 37: 1065-72
14. Smith WG, Wang J, Dang A, Reeves C, Bibbs D, Faas FH. Lipoprotein susceptibility to oxidation in the macromolecular fraction of plasma: relation to plasma lipids and oleate/linoleate ratio in comparison with whole plasma in hypertriglyceridemia. Clin Chim Acta 2002; 316: 11-7